UNSPSC 51422403: Anecortave

This classification denotes an angiogenesis inhibitor with the molecular formula C21H28O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R5Y8O51589, chemically known as 17-alpha,21-dihydroxypregna-4,9(11)-diene-3,20-dione 21-acetate but generally known as anecortave, which bears US NIH Compound Identifier 111332. anecortave most often comes in base and acetate forms. World Health Organization schedules anecortave in its Anatomical Therapeutic Chemical (ATC) Classification.

Most nations schedule anecortave under HS 29372900 and SITC 54153. As of Q4 2014, ANECORTAVE remains the US FDA Preferred Term for this commodity. SMILES: CC(=O)OCC(=O)C1(CCC2C1(CC=C3C2CCC4=CC(=O)CCC43C)C)O.

UNSPSC 51422403 Anecortave is a Commodity code that does not reflect the work actually being solicited under it in recent state and local opportunities. The two opportunities tagged to this code involve naloxone procurement and therapeutic pharmacy initiatives — neither of which relates to anecortave, an ophthalmic pharmaceutical agent. Seminole County, Florida posted an IFB on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health support, with quarterly deliveries and a two-year contract term plus one-year renewal option. The Texas Health and Human Services Commission issued an RFI in April 2026 to gather vendor capabilities on a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The code shows minimal relevant recent activity; the tagging mismatch suggests either a cataloging error in the source system or that this Commodity code is not actively used by state and local buyers for its nominal pharmaceutical scope.

The issuing bodies are a county health authority (Seminole County) and a state health agency (Texas HHS Commission). Geographic activity is concentrated in Florida and Texas. The Seminole County IFB closes July 26, 2023 (note: this date is in the past relative to the posting date and the current date of 2026-07-20, indicating potential source data quality issues), with electronic bid submission required and quarterly delivery obligations. Vendors must provide unit costs, maintain workers' compensation and professional liability insurance, pass E-Verify verification, and comply with federal requirements including the Clean Air Act and Federal Water Pollution Control Act; FEMA funding is noted as a potential source. The Texas RFI, with a response deadline of April 3, 2026, functions as market research rather than a competitive solicitation, seeking vendor experience with direct contracting, negotiated net pricing, and outcomes-based agreements outside traditional pharmacy benefit manager channels. Neither opportunity specifies explicit set-asides for disadvantaged enterprises.